Oxaliplatin-mediated Inhibition of Survivin Increases Sensitivity of Head and Neck Squamous Cell Carcinoma Cell Lines to Paclitaxel

Publisher： Bentham Science Publishers

E-ISSN： 1873-5576|10|7|660-669

ISSN： 1568-0096

Source： Current Cancer Drug Targets, Vol.10, Iss.7, 2010-11, pp. : 660-669

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

EGFR inhibition as a therapy for head and neck squamous cell carcinoma

By Loeffler-Ragg Judith   Schwentner Ilona   Sprinzl Georg M   Zwierzina Heinz  

Expert Opinion on Investigational Drugs, Vol. 17, Iss. 10, 2008-10 ,pp. : 1517-1531

Informa Healthcare

Access to resources Recommend Favorite

Pharmacotherapy for squamous-cell carcinoma of the head and neck

By Papaspyrou Giorgos   Werner Jochen A   Dietz Andreas  

Expert Opinion on Pharmacotherapy, Vol. 12, Iss. 3, 2011-02 ,pp. : 397-409

Informa Healthcare

Access to resources Recommend Favorite

Afatinib in the treatment of head and neck squamous cell carcinoma

By Ferrarotto Renata   Gold Kathryn A  

Expert Opinion on Investigational Drugs, Vol. 23, Iss. 1, 2014-01 ,pp. : 135-143

Informa Healthcare

Access to resources Recommend Favorite

Progress in Immunotherapy of Head and Neck Squamous Cell Carcinoma

By  

Current Molecular Pharmacology, Vol. 9, Iss. 3, 2016-08 ,pp. : 226-230

Bentham Science Publishers

Access to resources Recommend Favorite

Dual EGFR and COX-2 Inhibition as a Novel Approach to Targeting Head and Neck Squamous Cell Carcinoma

By  

Current Cancer Drug Targets, Vol. 9, Iss. 8, 2009-12 ,pp. : 931-937

Bentham Science Publishers

Access to resources Recommend Favorite